WebMD reports higher ad revenues, site traffic

Share this article:
Higher ad revenues and traffic to WebMD's physician and consumer web portals boosted second-quarter earnings, the healthcare information firm said.

Ad revenue jumped 32% during the April-June period, vs. the same period last year, to $100.6 million from $76 million. Traffic to the WebMD Health Network reached an average of 80.7 million unique users per month and total traffic of 1.8 billion page views during the quarter, increases of 35% and 22%, respectively, from a year ago. On the WebMD Professional Network, 1.5 million CME programs were completed.

That helped the firm swing to a second-quarter profit with earnings of $7.68 million, or 13 cents a share, compared with a loss of $11.7 million, or 25 cents, in the year-earlier quarter.

WebMD does not break down physician and consumer ad revenues, but a source told MM&M that revenue contributions from the two are roughly equal. Physician portal ad sales are derived almost exclusively from the pharmaceutical industry, the source said, while consumer portal sales come mostly from pharma with a growing portion from consumer packaged goods companies.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...